Evidence map›Paper›PMID 40224405›Full record

ArticleACS omega2025

pDILI_v1: A Web-Based Machine Learning Tool for Predicting Drug-Induced Liver Injury (DILI) Integrating Chemical Space Analysis and Molecular Fingerprints.

Sk Abdul Amin, Supratik Kar, Stefano Piotto

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sk Abdul AminDepartment of Pharmacy, Universita degli Studi di Salerno, Via Giovanni Paolo II 132, Fisciano 84084, Campania, Italy.ORCID https://orcid.org/0000-0003-4799-7322
Supratik KarChemometrics and Molecular Modeling Laboratory, Department of Chemistry and Physics, Kean University, 1000 Morris Avenue, Union, New Jersey 07083, United States.ORCID https://orcid.org/0000-0002-9411-2091
Stefano PiottoDepartment of Pharmacy, Universita degli Studi di Salerno, Via Giovanni Paolo II 132, Fisciano 84084, Campania, Italy.ORCID https://orcid.org/0000-0002-3102-1918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) represents a critical safety concern for drug development, regulatory oversight, and clinical practice, with substantial economic and public health implications. While predicting DILI risk in humans has garnered significant attention, the associated chemical space has remained insufficiently explored. This study addresses this gap through a comprehensive computational approach, leveraging machine learning (ML) to investigate structural determinants of DILI risk systematically. The study focuses on three key objectives: (i) exploring the chemical space and scaffold diversity associated with DILI; (ii) employing fragment-based approaches to identify structural alerts (SAs) that influence DILI risk; and (iii) developing supervised ML models to not only predict DILI risk but also elucidate the structural significance of molecular fingerprints. To broaden accessibility, we introduce pDILI_v1, a Python-based web application available at https://pdiliv1web.streamlit.app/. This user-friendly platform facilitates the prediction and visualization of DILI risk, enabling both experts and nonexperts to screen compounds effectively. Additional formats, including a Google Colab notebook and a graphical user interface (GUI) for Windows, ensure flexibility for diverse user needs. The proposed models demonstrate the potential for early identification of hepatotoxic risks in drug candidates, providing critical insights into drug discovery and development. By integrating ML-driven predictions with chemical space analysis, this research advances the field of drug safety evaluation, contributing to the development of safer pharmaceuticals and mitigating the risks of DILI.

Identifiers

PMID40224405
PMCPMC11983207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.